Logo

YOUR BLOOD CANCER doesn’t stand still.

Pinpoint where you are
with clonoSEQ®.

why clonoseq?

clonoSEQ is a test to measure minimal residual disease (MRD) to help you monitor, manage, and move forward with your blood cancer care.

LEARN MORE ABOUT clonoSEQ

MRD status icon

MRD is one of the strongest predictors of outcomes in blood cancers

LEARN MRD BASICS

Graph showing changes in disease over time

clonoSEQ monitors your cancer by assessing treatment response and detecting changes in disease

clonoSEQ AND YOU

Adaptive Assist logo

We offer a comprehensive reimbursement support program

GET PATIENT SUPPORT

Sign up today to receive useful information about managing blood cancer with clonoSEQ.

SIGN UP

If you have CLL, multiple myeloma, or B-ALL, talk with your doctor about tracking your MRD status with clonoSEQ today.

Questions to ask your doctorPhysician Finder

References to “blood cancer” on this webpage refer specifically to CLL, multiple myeloma, and B-ALL. Talk to your doctor about your options if you have another type of blood cancer and are interested in MRD testing.


This page is intended for a US-based audience.

clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT).

clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.